ClinicalTrials.gg
CompletedNCT01420549LANCEUpdated Jan 22, 2020Results posted

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

A Phase 3 interventional study of Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation. and Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation. in Hypercholesterolemia and Dyslipidemia, sponsored by Ache Laboratorios Farmaceuticos S.A.. Completed at 7 sites in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
41st of 57
129 · median 203
Started
2013
with 4 others
Phase 3
33 of 59
none open now
Registered
34th of 59
by date
Lead sponsor
1 of 59
Ache Laboratorios Farmaceuticos S.A.

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 41st largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2013, is one of 33 in phase 3, and was the 34th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to determine the non-inferiority between two different FDC (fixed-dose combination), measuring LDL-Cholesterol levels, in high risk patients with primary hypercholesterolemia or mixed dyslipidemia.

Read the detailed description

The primary efficacy variable was the percentage of LDL-C variation at the end of nine weeks of treatment, compared to baseline (pre-randomization), in participants who achieved LDL \<100 mg/dL were considered to have been successfully treated.

03

Conditions studied

  • Hypercholesterolemia
  • Dyslipidemia

Keywords

  • Hypercholesterolemia
  • Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 to 80 years;
  • Participants diagnosed with primary hypercholesterolemia or mixed dyslipidemia;
  • Participants must not have other comorbidities that may interfere with study evaluations;
  • Participants able to understand and adhere to the therapeutic scheme and to attend the study visits;
  • Participants who agree to maintain a low cholesterol diet throughout the study;
  • Participants who agree to discontinue previous medication for hypercholesterolemia treatment throughout the study;
  • Participants with hypercholesterolemia or mixed dyslipidemia with the following laboratory test results on the baseline visit: LDL-C level >130 mg/dl if were receiving prior treatment with statins; or LDL-C level >100 mg/dl if were receiving prior treatment with first generation statins; or LDL ≥160 mg/dL and ≤220 mg/dL and triglycerides ≤350 mg/dL if were not in prior treatment with statins.
  • Female participants in reproductive age with negative serum beta-hCG test result in the baseline visit who agree to use acceptable methods (oral contraceptives, injectable contraceptives, intrauterine device (IUD), hormonal implants, barrier methods, hormonal patch, tubal ligation or female participants who declare to perform non reproductive sexual practices); except surgically sterile (for example oophorectomy and hysterectomy), surgical sterilization or of the partner; or for at least one year;
  • Participants with laboratorial test results after treatment with Simvastatin 20 mg for four weeks with LDL-C level ≥100 mg/dl.

Exclusion criteria

Exclusion Criteria:

  • Heart failure class III or IV (- New York Heart Association);
  • Blood dyscrasia;
  • Unstable angina pectoris;
  • Myocardial infarction in the last 3 months;
  • Planning for CABG (coronary artery bypass graft), peripheral or carotid percutaneous intervention for the next 90 days;
  • Renal insufficiency: estimated (GFR) \< 30 ml/min/m2;
  • History of alcoholism that, at the investigator's discretion, could compromise the drug treatment compliance;
  • Participants with comorbidities that hinder the interpretation of results or contraindicate the lipid-lowering therapy [uncontrolled hypothyroidism (thyroid-stimulating hormone [TSH] > 8 mUI/mL); uncontrolled diabetes ( [HbA1c] > 8%); active hepatic disease; antiretroviral therapy for , neoplasm (except for adequately treated skin cancer within the past 5 years), concomitant therapy (transplant receivers and rheumatic disease);
  • Uncontrolled systemic arterial hypertension;
  • to any component of the product;
  • Participant who has participated in clinical trial protocols in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to the patient;
  • Any observational finding (clinical/ physical evaluation), laboratory abnormality, disease or therapy that is interpreted by the investigator as a risk to the research participant's participation in the clinical trial;
  • (AST) or alanine aminotransferase (ALT) more than two times the normal upper limit of the central laboratory reference range after treatment with Simvastatin 20 mg for four weeks;
  • Creatine phosphokinase (CPK) more than three times the normal upper limit of the central laboratory reference range after treatment with Simvastatin 20 mg for four weeks.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Rosuvastatin + Ezetimibe

    Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was \<100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.

    Drug: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.

  • Active comparator
    Simvastatin + Ezetimibe

    Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was \<100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.

    Drug: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.

Interventions

  • DrugRosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.

    Drug page: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.

    Also known as: Lance

  • DrugSimvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.

    Drug page: SimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.

    Also known as: Vytorin

06

What researchers measure

Primary outcomes

  1. Reduction of LDL Cholesterol Levels

    The primary efficacy variable was the percentage of LDL-C variation at the end of nine weeks of treatment, compared to baseline (pre-randomization), in participants who achieved LDL \<100 mg/dL were considered to have been successfully treated.

    Time frame: Baseline compared to the end of 9 weeks of treatment

07

Results

Posted Jan 22, 2020

Participant flow

Participants were recruited at 7 research centers between March 2013 and July 2014. The first participant was enrolled on March 21, 2013 and the last participant was enrolled in July, 2014.

Participant flow — Overall Study
MilestoneRosuvastatin + EzetimibeSimvastatin + Ezetimibe
Started6663
Completed5958
Not completed75
Withdrew: Adverse event11
Withdrew: Lost to follow-up22
Withdrew: Protocol violation01
Withdrew: Non-adherence to medication41

Outcome measures

PrimaryReduction of LDL Cholesterol Levels

The primary efficacy variable was the percentage of LDL-C variation at the end of nine weeks of treatment, compared to baseline (pre-randomization), in participants who achieved LDL \<100 mg/dL were considered to have been successfully treated.

Time frame:
Baseline compared to the end of 9 weeks of treatment
Reported as:
Least squares mean · percent change of LDL
Reduction of LDL Cholesterol Levels
percent change of LDLRosuvastatin + EzetimibeSimvastatin + Ezetimibe
Reduction of LDL Cholesterol Levels-39.45 (-43.53 to -35.08)-29.13 (-34.05 to -23.85)
Statistical analysis
  • Rosuvastatin + Ezetimibe vs Simvastatin + Ezetimibe · ANCOVA · p = 0.0013 · Median difference (final values): -10.32 · 95% CI -16.94 to -3.70Mean Percentage Change LDL- C (%)

Adverse events

Collected over 9 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin + Ezetimibe0/66 (0%)0/66 (0%)2/66 (3%)
Simvastatin + Ezetimibe0/63 (0%)2/63 (3.2%)4/63 (6.3%)
Most frequent serious events
Most frequent serious events
EventRosuvastatin + EzetimibeSimvastatin + Ezetimibe
Pulmonary tuberculosisInfections and infestations0/661/63
Pneumonia NOSInfections and infestations0/661/63
Most frequent other events
Most frequent other events
EventRosuvastatin + EzetimibeSimvastatin + Ezetimibe
MyalgiaMusculoskeletal and connective tissue disorders2/664/63

Baseline characteristics

All randomized participants who received at least one dose of treatment.

Age, Categorical
Age, Categorical(Participants)Rosuvastatin + EzetimibeSimvastatin + EzetimibeTotal
<=18 years000
Between 18 and 65 years494190
>=65 years172239
Age, Continuous
Age, Continuous(years)Rosuvastatin + EzetimibeSimvastatin + EzetimibeTotal
Mean59.39 ± 8.759.16 ± 9.659.28 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin + EzetimibeSimvastatin + EzetimibeTotal
Female5553108
Male111021
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rosuvastatin + EzetimibeSimvastatin + EzetimibeTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American6612
White514596
More than one race91221
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Rosuvastatin + EzetimibeSimvastatin + EzetimibeTotal
Brazil6663129
08

Study locations

7 sites
  • Centro de Pesquisas em Diabetes e Doenças Endócrino-Metabólicas- UFC
    Fortaleza, Ceará, Brazil
  • Centro de Pesquisas Médicas Básica e Clínica
    Recife, Pernambuco, Brazil
  • CCBR Brasil Centro de Pesquisas e Análises Clínicas
    Rio de Janeiro, Brazil
  • CEPIC Centro Paulista de Investigação Clínica
    São Paulo, Brazil
  • FGM - Clínica Paulista de Doenças Cardiovasculares
    São Paulo, Brazil
  • Hospital do Rim e Hipertensão
    São Paulo, Brazil
  • Universidade Federal de São Paulo
    São Paulo, Brazil
09

References and documents

Publications

  • Vattimo ACA, Fonseca FAH, Morais DC, Generoso LF, Herrera R, Barbosa CM, de Oliveira Izar MC, Cardoso RA, Zung S. Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. Curr Ther Res Clin Exp. 2020 Jul 28;93:100595. doi: 10.1016/j.curtheres.2020.100595. eCollection 2020. PubMed 32904162 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Aug 19, 2011
Start
Mar 2013
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Jan 22, 2020
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01420549
Responsible party
Sponsor
First posted
Aug 19, 2011
Start date
Mar 2013
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Jan 22, 2020
Last update
Jan 22, 2020

Study contacts

Francisco Fonseca, physician
principal investigator · Universidade Federal de São Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion